文献速递关节外科

阿司匹林与其他抗凝药用于择期全髋与全膝关节置换术后静脉血栓栓塞初始预防:伞状综述与荟萃分析

Aspirin Versus Other Anticoagulants for the Initial Prevention of Venous Thromboembolism Following Elective Total Hip and Knee Arthroplasty: An Umbrella Review and Meta-Analysis.
PubMed 文献 · J Arthroplasty · 2025-06-11

该伞状综述与荟萃分析纳入19篇系统综述和荟萃分析,评估阿司匹林预防初次或翻修全髋与全膝关节置换术后静脉血栓栓塞的疗效与安全性。阿司匹林组深静脉血栓风险与非阿司匹林组相当(OR=1.20,95%CI 0.86-1.68),总出血风险显著降低30%(0.33% vs 1.05%,OR=0.7,95%CI 0.58-0.85)。作者认为阿司匹林是可行的药物预防选择。

要点

  • 阿司匹林组深静脉血栓风险与非阿司匹林组相当(OR=1.20,95%CI 0.86-1.68)。
  • 阿司匹林显著降低总出血风险30%(0.33% vs 1.05%,OR=0.7,95%CI 0.58-0.85)。
  • 肺栓塞风险两组无统计学显著差异(OR=1.26,95%CI 0.76-2.07,I²=94%)。

核心结论

  • 阿司匹林是初次或翻修全髋与全膝关节置换术后可行的药物预防选择,因其可获得性、成本效益、给药方便、无需常规血液监测且与其他抗凝药疗效相当。

研究设计与样本

  • 伞状综述与荟萃分析,检索PubMed、Web of Science、Scopus和Embase数据库(2023年9月7日),纳入19篇评估阿司匹林预防初次或翻修全髋与全膝关节置换术后静脉血栓栓塞疗效与安全性的系统综述和荟萃分析。
  • 采用「系统综述方法学质量评估工具2」评估纳入研究方法学质量,由两名独立评价者提取血栓栓塞事件、出血和死亡率数据。

主要发现

  • 阿司匹林组与非阿司匹林组深静脉血栓总体风险相当(OR=1.20,95%CI 0.86-1.68)。
  • 阿司匹林降低肺栓塞风险0.58%,其他抗凝药降低0.6%,无统计学显著差异(OR=1.26,95%CI 0.76-2.07,I²=94%)。
  • 阿司匹林较其他抗凝药显著降低总出血风险30%(0.33% vs 1.05%,OR=0.7,95%CI 0.58-0.85,I²=2%)。
  • 全因死亡率阿司匹林组(0.18%)与其他抗凝药组(0.14%)无显著差异(OR=1.25,95%CI 0.79-1.97)。

临床怎么用

  • 作者认为,基于可获得性、成本效益、给药方便、无需常规血液监测及与其他抗凝药疗效相当,阿司匹林可作为初次或翻修全髋与全膝关节置换术后可行的药物预防选择。

局限性

  • 肺栓塞分析异质性I²=94%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reducing venous thromboembolism (VTE) events is crucial to improving outcomes following total joint arthroplasties. Aspirin, low-molecular-weight heparin, factor Xa inhibitors, and warfarin have been investigated to prevent VTE after surgery, but the best option remains uncertain. Our study aimed to clarify aspirin's prophylactic role in hip and knee arthroplasty through an umbrella analysis. METHODS: PubMed, Web of Science, Scopus, and Embase databases were queried on September 7, 2023, to identify all published systematic reviews and meta-analyses evaluating the efficacy and safety of aspirin in preventing VTE after primary or revision total hip and total knee arthroplasties. The methodological quality of the included studies was assessed using the "A Measurement Tool to Assess Systematic Reviews 2" critical appraisal tool. There were two independent reviewers who extracted data focusing on thromboembolic events, bleeding, and mortality rates. RESULTS: There were 19 systematic reviews and meta-analyses included. The overall risk of deep venous thrombosis was comparable in the aspirin versus nonaspirin group (odds ratio [OR] = 1.20; 95% confidence interval [CI] = 0.86 to 1.68). Aspirin reduced the risk of pulmonary emboli by 0.58%, while other anticoagulants showed a similar reduction of 0.6%, which was not statistically significant (OR = 1.26; 95% CI = 0.76 to 2.07; I2 = 94%). Aspirin significantly reduced total bleeding risk by 30% compared to other anticoagulants (0.33 versus 1.05%; OR = 0.7; 95% CI = 0.58 to 0.85; I2 = 2%). The all-cause mortality rate did not significantly differ between aspirin (0.18%) and other anticoagulants (0.14%) (OR = 1.25; 95% CI = 0.79 to 1.97). CONCLUSIONS: Aspirin is a viable chemoprophylactic option following primary or revision total hip and knee arthroplasty due to its availability, cost-effectiveness, ease of administration, lack of routine blood monitoring requirement, and comparative effectiveness to other anticoagulants.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Borazjani R, Khorram R, Ghorbani M, et al. Aspirin Versus Other Anticoagulants for the Initial Prevention of Venous Thromboembolism Following Elective Total Hip and Knee Arthroplasty: An Umbrella Review and Meta-Analysis. J Arthroplasty. 2025. PMID: 40513910. doi:10.1016/j.arth.2025.06.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。